CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Myeloid-Derived Growth Factor Protects Against Pressure Overload–Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca2+-ATPase Expression in Cardiomyocytes Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction

Expert Opinion2020 Oct 14;41(39):3769-3773.

JOURNAL:Eur Heart J. Article Link

The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions

F Crea. Keywords: HF; non-pharmacological interventions; mechanisms

Full Text PDF